Latest Strategy News

Atomo Diagnostics has responded to ASX queries confirming it first held market-sensitive information after Lumos Diagnostics’ FDA CLIA waiver approval for FebriDx. The company defended its trading halt and capital raise timing, asserting full compliance with ASX Listing Rules.

Life360 has reported its first full year of profitability alongside a 32% revenue surge to $489.5 million in 2025, driven by user growth, new Pet GPS subscriptions, and a strategic advertising platform acquisition.

AuKing Mining has agreed to acquire the Tundulu Rare Earths Project in Malawi, a large and under-explored carbonatite complex with strong historical drilling results. The acquisition is supported by a $3 million capital raise to fund exploration and drilling activities.

Lithium Plus Minerals has secured A$2.15 million through a discounted placement, backed by cornerstone investor Suzhou CATH and institutional buyers, to fund development and exploration at its Bynoe lithium project.

Krakatoa Resources has restructured its acquisition of the Zopkhito Antimony-Gold Project in Georgia, adopting a staged earn-in model that reduces upfront payments and prioritises capital deployment into exploration and development activities for 2026.

IRIS Metals has fortified its balance sheet with a A$5.5 million placement and is progressing towards an updated lithium-rubidium resource at Beecher while executing a farm-in deal for a tungsten project in Montana, reinforcing its diversified US critical minerals strategy.

Naos Small Cap Opportunities Company has kicked off an on-market buy-back program set to repurchase up to 10% of its issued shares over the next year, signalling a notable capital management move.

Fredon, NRW Holdings’ electrical and mechanical arm, has landed contracts worth around $160 million spanning major infrastructure, health, and electric vehicle projects across Australia, with work scheduled through to mid-2028.

Immuron Limited’s unaudited Q3 FY26 sales rose 16% to AUD 1.5 million, driven by Travelan’s expanding footprint in Australia, Canada, and the US despite a stronger Australian dollar.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

K2 Asset Management has decided to wind down its K2 Australian Small Cap Hedge Fund Complex ETF after a strategic review found it unlikely to meet profitability targets. The closure paves the way for reallocating capital to higher-growth areas and streamlining product offerings.

Eden Innovations has unveiled EdenShield®, a new division focused on commercialising advanced carbon nanotube-enhanced materials and dual-fuel systems for defence and critical infrastructure, aiming to tap into a rapidly expanding global aerospace and defence market.